William Blair analyst Raju Prasad maintained a Buy rating on Krystal Biotech Inc (KRYS) today. The company’s shares opened today at $35.68, close to its 52-week high of $36.89.
According to TipRanks.com, Prasad is a 5-star analyst with an average return of 23.9% and a 64.1% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Global Blood Therapeutics, and Logicbio Therapeutics Inc.
Currently, the analyst consensus on Krystal Biotech Inc is a Strong Buy with an average price target of $43.38, representing a 21.6% upside. In a report issued on May 6, Cowen & Co. also assigned a Buy rating to the stock.
See today’s analyst top recommended stocks >>
Based on Krystal Biotech Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $4.11 million. In comparison, last year the company had a GAAP net loss of $2.15 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments. The company was founded by Suma M. Krishnan in December 2017 and is headquartered in Pittsburgh, PA.
